Bli medlem
Bli medlem

Du är här

2016-10-26

Oasmia convenes an extraordinary general meeting on the 21 November, 2016.

es an extraordinary general meeting on the 21 November, 2016.

Uppsala, Sweden, October 26, 2016 -- Oasmia Pharmaceutical AB (publ) (“Oasmia”
or the “Company”) hereby announces that the Company convenes to an
extraordinary general meeting.

Uppsala, Sweden, 2016-10-26 08:30 CEST (GLOBE NEWSWIRE) --

As previously announced on October 24 2106 Oasmia intended to convene to an
extraordinary general meeting the 21 November 2016. The notice to the
extraordinary general meeting is published in its entirety below. The notice
will be published in Post- och Inrikes tidningar on Thursday 27 October, 2016
and on the same day an announcement will be made in the newspaper Dagens
Nyheter.

NOTICE OF EXTRAORDINARY GENERAL MEETING IN OASMIA PHARMACEUTICAL AB (PUBL)

The shareholders of Oasmia Pharmaceutical AB (publ), 556332-6676, are hereby
given notice of the extraordinary general meeting on 21 November 2016, at 10.30
a.m., at the offices of the company, Vallongatan 1, 752 28 Uppsala. The
registration opens at 10.00 a.m.

Registration etc.

Shareholders who wish to participate in the general meeting must be recorded in
the share register kept by Euroclear Sweden AB on 15 November 2016, and give
notice of intent to participate to the company not later than 4.pm. on 17
November 2016, either by letter to Oasmia Pharmaceutical AB, Vallongatan 1,
SE-752 28 Uppsala, Sweden, by fax: +46 18 51 08 73 or by e-mail:
info@oasmia.com, and specify the number of assistants. Shareholders that have
their shares registered in the name of a nominee must, in addition to giving
notice of participation in the meeting, temporarily be recorded in the share
register in their own names to be able to participate in the meeting. Such
registration must be effectuated on 15 November 2016, at the latest.
Shareholders represented by an agent shall to the agent issue a written and
dated proxy, and shall submit the proxy to the company prior to the general
meeting. The proxy and any other authorization documents, such as
registrations, shall be available at the meeting. Such authorization documents
should also be attached to the notice. For those who wish to be represented by
agents, the company provides proxy templates which are available on the
company’s website, http://www.oasmia.com.

Agenda

1. Election of chairman of the meeting
2. Preparation and approval of the voting list
3. Approval of the agenda
4. Election of one or two persons to verify the minutes in addition to the
chairman
5. Determination as to whether the meeting has been properly convened
6. Determination of the number of Directors
7. Election of board members and Chairman of the Board of Directors
8. Determination of remuneration to the to the Chairman of Board of Directors
9. Resolution on the board’s proposal to issue warrants, 2016:1
10. Resolution on
Alceco International S.A.
’s proposal to issue warrants, 2016:2
11. Closing of the meeting

The nomination committee proposes as follows

Notice of proposals in 6, 7 and 8 shall apply for the period until the end of
the next Annual General Meeting, otherwise the decisions from the Annual
General Meeting the 26 of September will remain unchanged.

Determination of the number of directors (item 6)

The shareholders of Oasmia decided at the Annual General Meeting the 26
September 2016 that the Board of Directors shall, for the period until the next
Annual General Meeting, compose of six ordinary Directors, no deputies.

The nomination committee has given notice of proposal, at the extraordinary
general meeting, that the Board of Directors shall be extended by one ordinary
board member and that it shall, consist of seven ordinary board members, no
deputies. The decision shall be conditional upon that the extraordinary General
Meeting in accordance with the proposals in paragraphs 7, 8, and 10.

Election of board members (item 7)

The shareholders of Oasmia decided at the Annual General Meeting the 26
September 2016 that the Board of Directors shall, for the period until the next
Annual General Meeting, re-elect Julian Aleksov, Horst Domdey, Bo Cederstrand,
Alexander Kotsinas, Lars Bergkvist and Hans Sundin as board members.

The nomination committee has given notice of proposal, at the extraordinary
general meeting, in addition to the board members elected at the Annual General
Meeting, to elect Anders Lönner as a member and also Chairman of the Board and
Julian Aleksov as member and Vice Executive Chairman of the Board.

Anders Lönner is born 1945 and is Executive Chairman of the Board of Directors
of Karo Pharma AB. Previous experience as President and CEO, board member of
Valeant Pharmaceuticals International Inc., President for Astra Läkemedel with
responsibilities including Astra’s Scandinavian subsidiary, President for Karo
Bio AB and Chairman of Läkemedelsindustriföreningen (LIF). Anders Lönner is
medicine Honorary Doctors at Karolinska Institutet.

The decision shall be conditional upon that the extraordinary General Meeting
in accordance with the proposals in paragraphs 6, 8,10.

Determination of remuneration to the Chairman of board of directors (item 8)

The nomination committee has given notice of proposal, at the extraordinary
general meeting, that the fee to the Chairman of the Board of Directors shall
be SEK 300 000.

The board’s proposal to issue warrants, 2016:1 (item 9)

The board of directors of Oasmia Pharmaceutical AB (publ) proposes that the
general meeting resolves to issue warrants and to transfer the warrants in
accordance with the following.

1 Issue of warrants

1.1 The board proposes that the general meeting resolves on
a directed issue of maximum 3 000 000 warrants, entailing an increase in the
company’s share capital on full exercise of the warrants amounting to a maximum
of SEK 300 000. The following terms shall apply.

1.2 The right to subscribe for warrants is only given to the
wholly owned subsidiary Oasmia Animal Health AB u.ä.t. Oasmia Incentive AB,
556519-8818, with a right and obligation to transfer the warrants in accordance
with section 2. No excess subscription is allowed.

1.3 The reason for derogation from the shareholders’
pre-emption rights is to implement an incentive programme through which
employees, by an own investment, participates in and works for a positive
growth of value of the company’s share for the period that the programme
covers, and to ensure that the company can keep and recruit qualified and
motivated personnel.

1.4 The warrants shall be issued free of charge.

1.5 Subscription is to take place within three weeks from
the day of the resolution to issue warrants. The board may extend the
subscription period.

1.6 Each warrant entitles the holder to subscribe for one
new share of series A in the company. Shares can be subscribed for based on the
warrants during the period from and including 24 November 2018 up to and
including 24 January 2019.

1.7 The subscription price per share shall correspond to 150
per cent of the volume-weighted average price for the series A shares in the
Company according to Nasdaq Stockholm’s official price list during the period
from and including 3 October 2016 up to and including 21 October 2016.

1.8 The shares subscribed for based on the warrants shall
carry a right to participate in dividends for the first time on the next record
date for dividends which occurs after subscription is completed.

1.9 Warrants held by the subsidiary that are not transferred
in accordance with section 2 or that is repurchased from participants, may be
cancelled through a decision by the board of directors, following consent from
the board of directors of the subsidiary. The cancellation shall be notified to
the Swedish Companies Registration Office.

1.10 The board, or the person appointed by the board, is
authorised to execute the decision and to make such minor adjustments which may
prove necessary in conjunction with registration with the Swedish Companies
Registration Office.

1.11 For complete terms, see appendix.

2 Approval of transfer of warrants

2.1 Entitlement to acquire warrants

The right to acquire warrants from the subsidiary is to accrue to the following
categories of employees:

Category Maximum no. of warrants
per person
--------------------------------------------------------------------------------
A. The executive committee, excluding the executive 750 000
chairman of the board (4 persons)
--------------------------------------------------------------------------------

The right to acquire warrants from the subsidiary shall only vest in the
persons that, at the end of the application period, has not terminated his or
her employment and is not terminated by the company.

Warrants may also be offered to future employees, whereby the same or
equivalent terms shall apply, meaning, e.g., that the then current market value
shall apply.

Allotment requires that the warrants can be legally acquired and that, in the
board’s opinion, such acquisition can take place using a reasonable amount of
administrative and financial resources.

2.2 Application and allotment

Application for acquisition of warrants shall be made from and including 22
November 2016 to and including 24 November 2016. The board is authorised to
extend the application period and to instruct upon an equivalent application
period for new employees that acquires shares after the end of the initial
application period.

Should not all warrants have been allotted after all applied for warrants have
been allotted, the remaining warrants may be allotted to other participants
within either category, whereby the board of directors shall decide upon the
allotment based on category, staff category and the number of warrants applied
for. Such allotment may result in that the maximum number of warrants per
person is exceeded.

The board of directors of the company decides upon the final allotment.

2.3 Price and payment etc.

The warrants shall be transferred on market terms at a price which is
established based on a calculated market value for the warrants, applying the
Black & Scholes valuation model. For acquisitions made by new staff after the
initial applicatio...

Författare SSE

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.